gizmodo.com/psilocybin-depr...
This is an article from Nov '22 about MROC and Compass Pathways Psilocybin clinical trial that is still ongoing this year. I thought it would be helpful to post it for everyone to see the progress going on.
Here's a excerpt from the article...go to the link to read the whole story...
..."A study out this week is the largest of its kind to suggest that psilocybin—the key ingredient in psychedelic mushrooms—can be a potential treatment for depression. The randomized trial found that people with treatment-resistant depression who received a large dose of psilocybin along with psychological support experienced a significant reduction in symptoms up to three weeks later, as compared to those who took a much smaller dose of psilocybin.
The research is being funded by UK-based company Compass Pathways, which is hoping to develop its own proprietary form of synthetic psilocybin as a treatment for depression and other mental health conditions. Their latest results come from a Phase IIb trial that was conducted across 10 countries, including the U.S, and involved 233 volunteers with depression that hadn’t responded to at least two other treatments.
The volunteers were randomized to be given a single dose of psilocybin at three varying strengths: 1 milligram, 10 milligrams, or 25 milligrams. Before the trial, all the participants were given counseling to prepare them for the psychedelic experience. Following the treatment, they were monitored and told to focus inward while listening to a specially designed music playlist for about six hours. They then received two counseling sessions—the first a day later and the second a week later—meant to help them process the insights they might have gotten during the psilocybin trip. Finally, their mental health outcomes were tracked for 12 weeks.
The lowest dose of psilocybin that people received was intended as a control, since it was expected to have little to no therapeutic effect. Compared to this control dose, people on 25 milligrams of psilocybin experienced a significant reduction in symptoms from their baseline up to three weeks later. Those on the 10-milligram dose experienced a greater reduction of their symptoms as well, but the difference wasn’t statistically significant compared to those who took the 1-milligram dose. The findings were published Wednesday in the New England Journal of Medicine."